Neurocrine Biosciences (NBIX) Research & Development (2010 - 2026)

Neurocrine Biosciences' Research & Development history runs 17 years deep, the most recent figure standing at $296.2 million for Q1 2026.

• Quarterly Research & Development rose 12.54% year-over-year to $296.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $819.4 million (up 25.81% YoY) and the FY2025 annual result came in at $1.0 billion, up 38.93% from the prior year.
• Research & Development was $296.2 million for Q1 2026 at Neurocrine Biosciences, up from $258.2 million in the prior quarter.
• Across five years, Research & Development topped out at $296.2 million in Q1 2026 and bottomed at $5.0 million in Q1 2024.
• A 5-year average of $135.5 million and a median of $139.5 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development sank 96.42% — and 2025, when it soared 5164.0%.
• Neurocrine Biosciences' Research & Development stood at $118.0 million in 2022, then gained by 16.53% to $137.5 million in 2023, then surged by 34.98% to $185.6 million in 2024, then surged by 39.12% to $258.2 million in 2025, then rose by 14.72% to $296.2 million in 2026.
• Business Quant data shows NBIX's Research & Development at $296.2 million in Q1 2026, $258.2 million in Q4 2025, and $250.0 million in Q3 2025.